Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A NOTCH2 pathogenic variant alters the osteoblast and vascular cell transcriptome of mouse femurs.

Bone·2026
Same author

Inactivation of Hes1 in Skeletal Undifferentiated Cells Increases Bone Volume.

Endocrinology·2026
Same author

A novel variant of NOTCH2 causes skeletal fragility.

Bone·2025
Same author

Role of Notch signaling in corticalization.

Journal of endocrinological investigation·2025
Same author

NOTCH2 disrupts the synovial fibroblast identity and the inflammatory response of epiphyseal chondrocytes.

The Journal of biological chemistry·2025
Same author

A NOTCH3 pathogenic variant influences osteogenesis and can be targeted by antisense oligonucleotides in induced pluripotent stem cells.

PloS one·2025

Related Experiment Video

Updated: Jun 20, 2026

Preparation Of Gushukang (GSK) Granules for In Vivo and In Vitro Experiments
06:16

Preparation Of Gushukang (GSK) Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

Growth factor control of bone mass.

Ernesto Canalis1

  • 1Department of Research, Saint Francis Hospital and Medical Center, Hartford, Connecticut 06105-1299, USA. ecanalis@stfranciscare.org

Journal of Cellular Biochemistry
|September 1, 2009
PubMed
Summary

This study explores how growth factors control bone mass. It explains that osteoblasts, which form bone, are influenced by factors like BMPs and Wnt that promote their differentiation. IGF-I supports mature osteoblast function and prevents their death. Extracellular antagonists modulate these factors, and changes in their activity may contribute to osteoporosis. Current therapies aim to target these factors or their antagonists, but more clinical trials are needed to ensure safety and effectiveness.

Keywords:
bone mass regulationosteoblast signalinganabolic therapy for osteoporosisgrowth factor function in bone

Frequently Asked Questions

Related Experiment Videos

Last Updated: Jun 20, 2026

Preparation Of Gushukang (GSK) Granules for In Vivo and In Vitro Experiments
06:16

Preparation Of Gushukang (GSK) Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

Area of Science:

  • Bone biology within endocrinology
  • Growth factor signaling in skeletal development
  • Osteoporosis treatment research in clinical medicine

Background:

Osteoblasts regulate bone formation through replication, differentiation, and survival. Platelet-derived and fibroblast growth factors influence cell proliferation. BMPs and Wnt promote osteoblast differentiation. IGF-I enhances mature cell function and prevents death. No prior work had resolved how extracellular antagonists modulate these pathways. This gap motivated investigation into growth factor interactions. Prior research has shown these factors affect bone mass. Their modulation may influence osteoporosis. No prior work had clarified how antagonists alter bone mass. This uncertainty drove the current synthesis.

Purpose Of The Study:

This study aims to clarify how growth factors control bone mass. It focuses on pre-osteoblast replication and differentiation. It also examines mature osteoblast function. The role of extracellular antagonists is explored. The goal is to understand their role in osteoporosis. The study highlights BMPs, Wnt, and IGF-I. It emphasizes how these factors are modulated. The purpose is to inform anabolic therapies for bone diseases.

Main Methods:

The authors reviewed literature on growth factor signaling in bone. They analyzed how BMPs and Wnt induce osteoblast differentiation. They examined IGF-I's role in mature osteoblast function. They considered extracellular antagonists' effects. They evaluated clinical relevance of these findings. They synthesized data from multiple studies. They focused on anabolic therapies for osteoporosis. They assessed current therapeutic approaches and their limitations.

Main Results:

BMPs and Wnt induce mesenchymal cell differentiation toward osteoblasts. IGF-I stimulates mature osteoblast function and prevents cell death. Extracellular antagonists modulate BMP, Wnt, and IGF-I activity. Growth factor synthesis changes may contribute to osteoporosis. Antagonist expression or binding changes correlate with bone mass. IGF-I administration is a current anabolic therapy. Neutralizing antagonists is another approach. Targeting therapies to bone is ideal to avoid side effects.

Conclusions:

Growth factors control bone mass through replication, differentiation, and survival. BMPs and Wnt are key for osteoblast differentiation. IGF-I supports mature cell function and prevents death. Extracellular antagonists modulate these pathways. Their altered expression may affect bone mass. Current therapies target these factors or their antagonists. Targeting should be specific to bone to avoid side effects. Clinical trials are needed to assess long-term safety and efficacy.

BMPs and Wnt induce mesenchymal cells to differentiate into osteoblasts, which is essential for bone formation.

IGF-I stimulates the function of mature osteoblasts and prevents their death, supporting bone formation.

Targeting therapies specifically to bone can prevent non-skeletal side effects, which is a key concern in osteoporosis treatment.

Extracellular antagonists modulate the activity of BMPs, Wnt, and IGF-I, influencing bone mass and osteoporosis risk.

Current approaches include administering growth factors like IGF-I or neutralizing extracellular antagonists.

Clinical trials are required to determine the long-term effectiveness and safety of novel anabolic agents.